TWM
CRSP icon

Thrive Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Thrive Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,100
Closed -$201K – 244
2025
Q3 		$201K Buy
+3,100
New +$178K 0.03% 237
2024
Q2 		– Sell
-3,100
Closed -$211K – 221
2024
Q1 		$211K Buy
+3,100
New +$222K 0.04% 201

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GP
GSK plc London $602M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thrive Wealth Management's CRSP Position: Q4 2025 in Review

Thrive Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,100 shares — an estimated $201K sold.

Thrive Wealth Management first reported a position in CRSP in Q1 2024 and held it in 2 quarters. The position peaked at $211K in Q1 2024. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Thrive Wealth Management reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Thrive Wealth Management sold 3,100 CRISPR Therapeutics shares in Q4 2025, an estimated $201K.
  • Thrive Wealth Management first reported a position in CRISPR Therapeutics in Q1 2024 and held it in 2 quarters.
  • Thrive Wealth Management's CRISPR Therapeutics position peaked at $211K in Q1 2024.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Thrive Wealth Management's 13F filing for Q4 2025, filed 12 Jan 2026.